Fibrinogen and Intraoperative Bleeding in Liver Transplant (FIB_TOF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04925843|
Recruitment Status : Completed
First Posted : June 14, 2021
Last Update Posted : November 29, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Liver transplantation is the only treatment for end-stage liver disease. It is a high-risk surgery that can cause heavy intraoperative bleeding. Bleeding and transfusions of blood products are themselves associated with several postoperative complications. Few data have suggested beneficial interventions that can decrease this bleeding. Such interventions are necessary in order to improve these patients' outcomes. In order to better understand the potential therapeutic targets, a better comprehension of the variables associated with such bleeding is essential. Several previous studies have demonstrated a weak association between usual clotting times and bleeding in this population. However, few studies have evaluated the association between the concentration of fibrinogen and bleeding in this population.
The primary objective of this study is to assess the association between preoperative serum fibrinogen concentration and the volume of intraoperative bleeding. The secondary objective is to assess the association between preoperative serum fibrinogen concentration and the number of red blood cell units transfused during the intraoperative and immediate postoperative periods.
The hypothesis of the study is that a low concentration of preoperative fibrinogen will be associated with an increase in intraoperative bleeding and red blood cell transfusions.
|Condition or disease|
|End Stage Liver DIsease Liver Transplant; Complications|
All patients who received a liver transplant between July 2008 and January 2021 at the Centre Hospitalier de l'Université de Montréal (CHUM) will be included. The effect of fibrinogen concentration, intraoperative bleeding, intraoperative and postoperative transfusions, as well as postoperative bleeding-related complications and mortality up to 1 year will be assessed. The analysis will be adjusted for several confounding factors, including other coagulation parameters. The main association model will be a multivariable linear regression.
This study will be used to further explore the association between fibrinogen concentration and bleeding in liver transplantation. These results may help certain clinical decisions, without suggesting any potential effect of fibrinogen correction on clinical outcomes. If an association is found, the bases will be put in place to build a clinical trial evaluating the effects of a preemptive transfusion of blood products correcting this value on clinical outcomes.
|Study Type :||Observational|
|Actual Enrollment :||612 participants|
|Official Title:||Association Between Fibrinogen Concentration and Intraoperative Bleeding in Liver Transplantation: a Retrospective Observational Study|
|Actual Study Start Date :||July 15, 2019|
|Actual Primary Completion Date :||January 10, 2022|
|Actual Study Completion Date :||January 10, 2022|
Patients undergoing liver transplant for end-stage liver disease
The investigators propose to conduct a retrospective cohort study to explore the association between fibrinogen concentration and intraoperative bleeding in patients who underwent a liver transplant between July 2008 and January 2021.
- Estimated blood loss per mass of red blood cells lost [ Time Frame: Up to 48 hours after surgery ]In milliliters
- Number of red blood cell transfusions during liver transplantation [ Time Frame: At the end of surgery ]Count
- Number of perioperative red blood cell transfusions [ Time Frame: From the beginning of surgery until 48 hours after surgery ]Count
- Occurrence of bleeding complications leading to reintervention and / or angioembolization [ Time Frame: 30 days after surgery ]Dichotomous
- Occurrence of early retransplantation [ Time Frame: 30 days after surgery ]Dichotomous
- One year survival [ Time Frame: One year after surgery ]Time to event
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Adult patients undergoing liver transplant.
- Use of cryoprecipitate or fresh frozen plasma after measurement of serum fibrinogen concentration prior to arrival in the operating room.
- Amyloid neuropathy or liver cancer
- Fulminant hepatitis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04925843
|Centre Hospitalier de l'Université de Montréal (CHUM)|
|Montréal, Quebec, Canada, H2X 3E4|
|Principal Investigator:||François Martin Carrier, MD, PhD||Centre hospitalier de l'Université de Montréal (CHUM)|
|Responsible Party:||Centre hospitalier de l'Université de Montréal (CHUM)|
|Other Study ID Numbers:||
|First Posted:||June 14, 2021 Key Record Dates|
|Last Update Posted:||November 29, 2022|
|Last Verified:||November 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
End Stage Liver Disease
Blood Loss, Surgical
Digestive System Diseases